SCHEMBL1359548

SCHEMBL1359548

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc2c(-c3cccc(O)c3)coc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.36
CYP3A4 P08684 3/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
ALOX15 P16050 3/20 0.35
ALOX12 P18054 3/20 0.35
RET P07949 1/20 0.34
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
EGFR P00533 1/20 0.33
PIK3CA P42336 1/20 0.32
PTPN5 P54829 1/20 0.32
PRKDC P78527 1/20 0.32
ABCB1 P08183 1/20 0.32
TDP2 O95551 1/20 0.32
MAOA P21397 1/20 0.31
MAOB P27338 1/20 0.31
HSD17B1 P14061 1/20 0.31
HSD17B2 P37059 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1358251 0.88 CYP3A4 (0.38) CYP3A4ALOX15ALOX12
SCHEMBL1359206 0.87 BRD4 (0.39) CYP3A4EGFRTDP2
SCHEMBL1359893 0.86 ERCC5 (0.43) CYP3A4PPARGPPARDPPARA
SCHEMBL1360035 0.85 BRD4 (0.40) CYP3A4PIK3CAMAOB
SCHEMBL1360136 0.85 CYP3A4 (0.38) CYP3A4
SCHEMBL1359032 0.83 SIRT1 (0.43) CYP3A4HSD17B1HSD17B2
SCHEMBL1359880 0.83 CYP3A4 (0.36) CYP3A4PDE3BPDE3A
SCHEMBL1359875 0.82 CYP3A4 (0.49) CYP3A4TDP2
SCHEMBL1358345 0.82 CYP3A4 (0.41) CYP3A4
SCHEMBL1358769 0.82 MAOB (0.45) CYP3A4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS BRAF 2984/4885CYP3A4 713/4885PDE3B 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.